Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran for Hereditary Angioedema 08 September
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million 04 September
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference 04 September
